Cleared Special

K113564 - EXSALT T7 WOUND DRESSING (FDA 510(k) Clearance)

Dec 2011
Decision
13d
Days
-
Risk

K113564 is an FDA 510(k) clearance for the EXSALT T7 WOUND DRESSING. Classified as Dressing, Wound, Drug (product code FRO).

Submitted by Exciton Technologies, Inc. (Edmonton, Alberta, CA). The FDA issued a Cleared decision on December 15, 2011 after a review of 13 days - a notably fast clearance cycle.

This device falls under the General & Plastic Surgery FDA review panel. As a Special 510(k), this submission covers a manufacturer modification to an existing cleared device rather than a new device introduction.

Device pattern: Iterative device modification. Low regulatory complexity profile. This Special 510(k) clearance confirms that the manufacturer's modifications remained within the established regulatory envelope of the original cleared device.

Submission Details

510(k) Number K113564 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received December 02, 2011
Decision Date December 15, 2011
Days to Decision 13 days
Submission Type Special
Review Panel General & Plastic Surgery (SU)
Summary Summary PDF
Regulatory Context
Review time vs. panel average
119d faster than avg
Panel avg: 132d · This submission: 13d
Pathway characteristics
Modification to existing cleared device.

Device Classification

Product Code FRO Dressing, Wound, Drug
Device Class -

Regulatory Peers - FRO Dressing, Wound, Drug

All 29
Devices cleared under the same product code (FRO) and FDA review panel - the closest regulatory comparables to K113564.
MiraChlor Antimicrobial Wound Solution
K252023 · Letus Corporation · Mar 2026
Promogran Prisma™ Collagen Matrix with ORC and Silver
K251999 · Solventum Germany GmbH · Mar 2026
LUOFUCON® Antimicrobial Wound Gel
K252028 · Huizhou Foryou Medical Co., Ltd. · Mar 2026
Redermax Antibacterial Wound Matrix
K251582 · Beijing Kreate Medical Co., Ltd. · Feb 2026
New Day Skin Spray
K252568 · Silk Holdings, Inc. · Jan 2026
SBC1 Cream
K250890 · Sioxmed, LLC · Jan 2026